MarketVIEW: Respiratory Syncytial virus vaccines

Executive summary
Commercial model – key outputs
Total predicted demand (doses 000s), all scenarios
Total global available market ($000s), all scenarios
Total global available market ($000s), infant
Total global available market ($000s), adult “at risk”
Total global available market ($000s), adult “universal”
The role of a RSV vaccine
Vaccine target populations: overview
Vaccine target populations: scenario definitions
RSV vaccine: infant target product profile
RSV vaccine: adult target product profile
Markets included in the model
Commercial model assumptions: infant scenario
Commercial model assumptions: adult scenarios
Model forecast comparisons: March 2010 v current model (May 2012)
Pricing methodology: infant and adults
Competitor landscape overview
MedImmune: MEDI-534 and MEDI-559 vaccines
Novavax: VLP RSV-F vaccine
Novavax: Phase I data
Preclinical vaccines
Vaccine pipeline summary
Estimated launch dates
Opportunities for new treatments
Review of latest epidemiology
Epidemiology: infants
Epidemiology: adults
Epidemiology: hospitalizations
Methodology: target populations
Methodology: coverage
Model forecast comparisons: Novavax/LEK analysis
Bibliography
About VacZine Analytics
Disclaimer
PAGES: 60 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form
Contents – Vaccine demand model (MS Excel-based)
Title sheet
Scenarion definitions
GRAND SUMMARY CHARTS
CHARTS VALUE
CHARTS VOLUME
CHARTS VOLUME – HIGH
VALUE SUMMARY – universal
VALUE SUMMARY – “at risk”
VALUE SUMMARY – infants
VOLUME SUMMARY – universal
VOLUME SUMMARY – “at risk”
VOLUME SUMMARY – infants
Country volume/population sheets
US
Canada
UK
Germany
France
Spain
Italy
Other EU
Japan
Brazil
India
China
Mexico
Country total populations – forecast to 2030 (Births, >18 yrs, >65 yrs)
Source material
US RSV
Japan RSV
US Pneumonia
Asthma/COPD epidemiology
CHF epidemiology
Cancer EPI
Pricing (infant)
Coverage (COPD and HF)
Back page
About VacZine Analytics
Disclaimer
WORKSHEETS: ~65